Skip to main content

Table 1 Demographic and baseline characteristics (safety population) by last dose in the dose-optimization phase

From: Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

Characteristic, mean (SD)

LDX

30 mg/d

(n = 28)

LDX

50 mg/d

(n = 70)

LDX

70 mg/d

(n = 44)

LDX

All Doses

(N = 142)

Age (years)

30.5 (9.54)

29.7 (10.71)

31.8 (11.46)

30.5 (10.70)

Weight (lb)

174.7 (43.64)

176.7 (35.22)

182.4 (36.17)

178.1 (37.14)

Height (in)

65.8 (4.30)

68.3 (3.73)

68.3 (3.77)

67.8 (3.97)

Body mass index (lb/in2)

28.2 (5.45)

26.6 (4.79)

27.4 (5.10)

27.2 (5.02)

Gender, n(%)

    

   Male/female

16 (57.1)/12 (42.9)

45 (64.3)/25 (35.7)

27 (61.4)/17 (38.6)

88 (62.0)/54 (38.0)

Race, n (%)

   White

21 (75.0)

65 (92.9)

41 (93.2)

127 (89.4)

   Black/African American

4 (14.3)

2 (2.9)

0

6 (4.2)

   Native Hawaiian/Pacific Islander

2 (7.1)

0

0

2 (1.4)

   Asian

1 (3.6)

2 (2.9)

2 (4.5)

5 (3.5)

   American Indian/Alaskan Native

0

0

1 (2.3)

1 (0.7)

   Other

0

1 (1.4)

0

1 (0.7)

Ethnicity, n (%)

Hispanic or Latino/

Not Hispanic or Latino

2 (7.1)/26 (92.9)

7 (10.0)/63 (90.0)

4 (9.1)/40 (90.9)

13 (9.2)/129 (90.8)

ADHD subtype, n (%)

   Inattentive

8 (28.6)

20 (28.6)

11 (25.0)

39 (27.5)

   Hyperactive/impulsive

1 (3.6)

3 (4.3)

1 (2.3)

5 (3.5)

   Combined

19 (67.9)

47 (67.1)

32 (72.7)

98 (69.0)

ADHD-RS-IV with adult prompts: scores at baseline, mean (SD)

    

   Total

37.8 (6.06)

35.8 (4.85)

38.4 (6.12)

37.0 (5.61)

   Inattentive

20.9 (3.15)

19.7 (3.45)

20.8 (3.66)

20.3 (3.49)

   Hyperactivity/impulsivity

16.9 (5.52)

16.1 (4.35)

17.6 (4.86)

16.7 (4.77)

  1. ADHD = attention-deficit/hyperactivity disorder; ADHD-RS-IV = ADHD Rating Scale IV; LDX = lisdexamfetamine dimesylate.